These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 20832836)

  • 1. Mutations of an antibody binding energy hot spot on domain III of the dengue 2 envelope glycoprotein exploited for neutralization escape.
    Gromowski GD; Roehrig JT; Diamond MS; Lee JC; Pitcher TJ; Barrett AD
    Virology; 2010 Nov; 407(2):237-46. PubMed ID: 20832836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus.
    Gromowski GD; Barrett AD
    Virology; 2007 Sep; 366(2):349-60. PubMed ID: 17719070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A DENV-2-type-specific monoclonal antibody binds to the DENV-complex-reactive antigenic site on envelope protein domain 3.
    Sarathy VV; Pitcher TJ; Gromowski GD; Roehrig JT; Barrett ADT
    J Gen Virol; 2017 Jun; 98(6):1299-1304. PubMed ID: 28631593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus.
    Gromowski GD; Barrett ND; Barrett AD
    J Virol; 2008 Sep; 82(17):8828-37. PubMed ID: 18562544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of dengue complex-reactive epitopes on dengue 3 virus envelope protein domain III.
    Matsui K; Gromowski GD; Li L; Schuh AJ; Lee JC; Barrett AD
    Virology; 2009 Feb; 384(1):16-20. PubMed ID: 19101005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal antibodies that bind to common epitopes on the dengue virus type 2 nonstructural-1 and envelope glycoproteins display weak neutralizing activity and differentiated responses to virulent strains: implications for pathogenesis and vaccines.
    Falconar AK
    Clin Vaccine Immunol; 2008 Mar; 15(3):549-61. PubMed ID: 18160621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epitope determinants of a chimpanzee Fab antibody that efficiently cross-neutralizes dengue type 1 and type 2 viruses map to inside and in close proximity to fusion loop of the dengue type 2 virus envelope glycoprotein.
    Goncalvez AP; Purcell RH; Lai CJ
    J Virol; 2004 Dec; 78(23):12919-28. PubMed ID: 15542644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of a dengue type-specific epitope on dengue 3 virus envelope protein domain III.
    Matsui K; Gromowski GD; Li L; Barrett AD
    J Gen Virol; 2010 Sep; 91(Pt 9):2249-53. PubMed ID: 20444995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes.
    Sukupolvi-Petty S; Austin SK; Purtha WE; Oliphant T; Nybakken GE; Schlesinger JJ; Roehrig JT; Gromowski GD; Barrett AD; Fremont DH; Diamond MS
    J Virol; 2007 Dec; 81(23):12816-26. PubMed ID: 17881453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential expression of domain III neutralizing epitopes on the envelope proteins of West Nile virus strains.
    Li L; Barrett AD; Beasley DW
    Virology; 2005 Apr; 335(1):99-105. PubMed ID: 15823609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions.
    de Alwis R; Smith SA; Olivarez NP; Messer WB; Huynh JP; Wahala WM; White LJ; Diamond MS; Baric RS; Crowe JE; de Silva AM
    Proc Natl Acad Sci U S A; 2012 May; 109(19):7439-44. PubMed ID: 22499787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation and characterization of a monoclonal antibody that cross-reacts with the envelope protein from the four dengue virus serotypes.
    León-Juárez M; García-Cordero J; Santos-Argumedo L; Romero-Ramírez H; García-Machorro J; Bustos-Arriaga J; Gutiérrez-Castañeda B; Sepúlveda NV; Mellado-Sánchez G; Cedillo-Barrón L
    APMIS; 2013 Sep; 121(9):848-58. PubMed ID: 23331315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational analysis of a neutralization epitope on the dengue type 2 virus (DEN2) envelope protein: monoclonal antibody resistant DEN2/DEN4 chimeras exhibit reduced mouse neurovirulence.
    Hiramatsu K; Tadano M; Men R; Lai CJ
    Virology; 1996 Oct; 224(2):437-45. PubMed ID: 8874504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica.
    Roehrig JT; Bolin RA; Kelly RG
    Virology; 1998 Jul; 246(2):317-28. PubMed ID: 9657950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genotypic Differences in Dengue Virus Neutralization Are Explained by a Single Amino Acid Mutation That Modulates Virus Breathing.
    Dowd KA; DeMaso CR; Pierson TC
    mBio; 2015 Nov; 6(6):e01559-15. PubMed ID: 26530385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive mapping of functional epitopes on dengue virus glycoprotein E DIII for binding to broadly neutralizing antibodies 4E11 and 4E5A by phage display.
    Frei JC; Kielian M; Lai JR
    Virology; 2015 Nov; 485():371-82. PubMed ID: 26339794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dengue virus type 2 envelope protein displayed as recombinant phage attachment protein reveals potential cell binding sites.
    Abd-Jamil J; Cheah CY; AbuBakar S
    Protein Eng Des Sel; 2008 Oct; 21(10):605-11. PubMed ID: 18669522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dengue virus envelope domain III immunization elicits predominantly cross-reactive, poorly neutralizing antibodies localized to the AB loop: implications for dengue vaccine design.
    Li XQ; Qiu LW; Chen Y; Wen K; Cai JP; Chen J; Pan YX; Li J; Hu DM; Huang YF; Liu LD; Ding XX; Guo YH; Che XY
    J Gen Virol; 2013 Oct; 94(Pt 10):2191-2201. PubMed ID: 23851440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genotype-specific neutralization and protection by antibodies against dengue virus type 3.
    Brien JD; Austin SK; Sukupolvi-Petty S; O'Brien KM; Johnson S; Fremont DH; Diamond MS
    J Virol; 2010 Oct; 84(20):10630-43. PubMed ID: 20702644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance analysis of an antibody that selectively inhibits dengue virus serotype-1.
    Zou G; Kukkaro P; Lok SM; Ng JK; Tan GK; Hanson BJ; Alonso S; MacAry PA; Shi PY
    Antiviral Res; 2012 Sep; 95(3):216-23. PubMed ID: 22771779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.